Pentoxifylline for Vascular Calcification in Kidney Disease

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

October 15, 2025

Study Completion Date

October 30, 2025

Conditions
Chronic Kidney DiseaseVascular CalcificationKidney Failure, Chronic
Interventions
DRUG

Pentoxifylline 400 MG Oral Tablet

Oral tablet, 400 mg, administered twice daily with food for 6 months. To be taken in addition to conventional medications for chronic kidney disease.

OTHER

Conventional Medications for Chronic Kidney Disease

This arm receives conventional medical management for chronic kidney disease (CKD). This includes medications and treatments as deemed necessary and appropriate by the participant's treating physician, according to established clinical guidelines for CKD. These may include, but are not limited to, medications for blood pressure control, management of diabetes, anemia treatment, mineral and bone disorder management, and fluid and electrolyte balance management. The specific medications and treatments are individualized and not dictated by the study protocol, but follow standard clinical practice for CKD.

All Listed Sponsors
lead

Mansoura University

OTHER

NCT06903689 - Pentoxifylline for Vascular Calcification in Kidney Disease | Biotech Hunter | Biotech Hunter